奥扎格雷-脑得生序贯治疗急性脑梗死的前瞻性药物经济学研究

Study of the drug pharmacoeconomics on the sequntial antimicrobial therapy of the ozagrel- Naodesheng capsule in the treatment of acute cerebral infarction

目的观察奥扎格雷-脑得生序贯治疗急性脑梗死的疗效与安全性,并对其进行药物经济学评价。方法前瞻性的随机双盲对照临床研究,2组均为132例急性脑梗死患者,试验组用奥扎格雷80 mg,ivgtt,bid,14 d后改用脑得生6粒,po tid;对照组用奥扎格雷80 mg,ivgtt,bid,均28 d。用药物经济学的最小成本分析法和成本—效果分析法进行评价。结果 2组临床疗效相近,以临床总有效率计C/E分别为141.8和205.4;ΔC/ΔE为894000。结论 2组费用差异有统计学意义;序贯治疗组更具成本—效果优势。

Objective To study of the drug pharmacoeconomics on the sequntial antimicrobial therapy of the ozagrel - Naodesheng capsule in the treatment of acute cerebral infarction. Methods It used prospective randomized doulbe - blind controlled design, the 132 samples of the trim group was administered with Ozagrel 80 mg twice a day. After fourteen days Naodesheng capsule was taken in 14 days, 6 pills each time, third times per day. The patients in control group was administered with oza- grel 80 mg twice a day for 28 days. The pharmacoeeonomics of minimum cost analysis and cost -effectiveness were used to analyze. Results The clinic curative effect of two group was intimate. The clinic total effective rate counting C/E was respectively 141.8 and 205.4. hE/hE was 894000. Conclusion There was significant difference in the cost in two groups. The cost - effect of sequntial antimicrobial therapy in curing a- cute cerebral infarction was more excellent.